medigraphic.com

2001, Number 4

<< Back Next >>

Rev Med Hosp Gen Mex 2001; 64 (4)

Ranitidine bismuth citrate (RBC) in eradication of Helicobacter pylori

Abdo FJM, Rodríguez VG, Bernal SF, Murguía DD

Language: Spanish
References: 32
Page: 205-209
PDF size: 79.49 Kb.


ABSTRACT

Ranitidine bismuth citrate (RBC) (GR122311X) is a new drug with antisecretory, cytoprotection and Helicobacter pylori eradication property. Several studys has showed that the association with clarithromycin and amoxicillin proved eradication rates ranging from 82 to 94% with minimal adverse events. The aim of the study was determinate the efficacy of RBC plus clarithromycin in the eradication of Helicobacter pylori in our population. Material and methods: Eighty patients with chronic gastritis and Helicobacter pylori infection were randomized to receive Ranitidine Bismuth Citrate (RBC) 400 mg BID plus clarithromycin 250 mg QDS or RBC placebo BID plus clarithromycin 250 mg QDS for two weeks in this prospective, double blind, parallel group study. Endoscopies, quick urea test and 13-C urea breath test were performed at beginning of the study. The eradication was proved by 13-C urea breath test one month after the end of the eradication therapy. Results: Ranitidine Bismuth Citrate 400 mg BID plus clarithromycin 250 mg QDS achieved 86% Helicobacter pyloriHelicobacter pylori eradication with minimal adverse events. The eradication was proved by a 13C-urea breath test. Conclusions: CRB associated to clarithromycin is an efficacy and safety alternative to Helicobacter pylori eradication. Further studys are required to determine the safety and efficacy of clarithomycin 500 mg BID or two antibiotics together for seven days in our population.


REFERENCES

  1. Marshall B. Warren JR. Unidentified curved bacillus on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-1275.

  2. Goodwin CS. Duodenal ulcer, Campylobacter pylori and the “leakin- roof” concept. Lancet 1988; 2: 1467.

  3. Levi S. Beardshall K. Haddad G et al. Campylobacter pylori and duodenal ulcer: the “gastrin-link” concept. Lancet 1989; 1: 1167.

  4. Forbes GM, Laser ME, Cullen DJE. Duodenal ulcer treated with Helicobacter pylori eradication: seven year follow-up. Lancet 1994; 343: 258-260.

  5. Graham DY, Lew GM, Klien PD. Effects of treatment of Helicobacter pylori infection on the long term recurrence of gastric or duodenal ulcer. Ann Internal Med 1992; 116: 705-708.

  6. Chiba N, Tao BV, Rademarker JW, Hunt RH. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-1727.

  7. Peterson W et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori. Am J Gastroenterol 1992; 87: 1274.

  8. Westblom TU, Duriex D. Enhancement of antibiotic concentrations in gastric mucosa by H2 antagonist. Dig Dis Sci 1991; 36: 25-28.

  9. Berstad A, Berstad K, Wilhelmsen I, Hattebakk JG, Nesje LB, Lauksen T. Clarithromycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-months follow-up. Aliment Pharmacol Therap 1995; 9: 197-200.

  10. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-991.

  11. Hentschel E, Brandstatter G, Dragosics B. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-312.

  12. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991; 324: 1043-1048.

  13. Prewett EJ, Nwoholo CU, Hudson M, Sawyerr AM, Fraser A. Pounder R. The effect of GR122311X, a bismuth compound with H2-antagonist activity on 24 hours intragastric acidity. Aliment Pharmacol Therap 1991; 5: 481-490.

  14. Bardhan KD, Dekkers CP, Lam SK, Nowak K, Schaffalitzky OB et al. GR122311X (ranitidine bismuth citrate) a new drug for the treatment of duodenal ulcer. Aliment Pharmacol Therap 1995; 9: 497-506.

  15. Forssell H, Nowak A, Tildesley G, Schutze K, Pare P, Sommer A, Lotay N. Comparison of GR122311X (ranitidine bismuth citrate) with ranitidine hydrochloride for the treatment of duodenal ulcer. GUT 1995; 37 (suppl 2): A435.

  16. Haeck PW, Peixe GR, Van Rensburg C, Dallaire C, Scrimgeous D, Lotay N. Effects of food on duodenal healing and H. pylori eradication during treatment with GR122311X (ranitidine bismuth citrate) GUT 1995; 37 (suppl 2): A434.

  17. Logan RP, Gummentt PA, Misiewicz JJ, Walker MM, Jameson J, Polson RJ, Karim QN, Duggan AE. The efficacy of ranitidine bismuth citrate (GR122311X) in the treatment of Helicobacter pylori infection. Gastroenterology 1992; 102 (4 pt 2): A 114.

  18. Peterson WL, Sontag SJ, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus clarithromycin is effective in the eradication oh Helicobacter pylori and prevention of duodenal ulcer relapse. Gastroenterology 1995; 108: A 190.

  19. Forster ER, Bedding AW, Taylor G, Smith JTL. Ranitidine bismuth citrate (GR122311X) and ranitidine do not affect gastric emptying in man. Gastroenterology 1994; 106 (4 pt 2): A 499.

  20. Ciociola AA, Koch KM, McSorley D, Snell CL, Webb DD. Safety and pharmacokinetics of ascending oral doses of GR122311X ranitidine bismuth citrate) a new bismuth compound with antisecretory properties. Gastroenterology 1992; 102 (4 pt 2): A 51.

  21. Bardhan KD, Dekkers CPM, Nowak A et al. GR122311X (ranitidine bismuth citrate) a new drug for the treatment of duodenal ulcer. Aliment Pharmacol Ther 1995; 9: 497-506.

  22. Logan RPH, Gummett PA, Misiewicz JJ et al. The efficacy of ranitidine bismuth citrate (GR122311X)in the treatment of Helicobacter pylori infection. Gastroenterol 1992; 102 (part 2): A 114.

  23. Wyeth JW, Pounder RE, Duggan AE et al. The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of the Helicobacter pylori. Alim Pharmacol Ther 1996; 10: 623-630.

  24. Peterson WI, Ciociola AA, Sykes DL, McSorley DJ. Weeb DD and the RBC H. pylori Study Group. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing their recurrence. Aliment Pharmacol Ther 1996; 10: 251-261.

  25. Bardhan KD, Dallaire C, Eisold H, Duggan AE. The treatment of duodenal ulcer with GR122311X (Ranitidine bismuth citrate) and clarithromycin. Gut 1995; 37 (suppl 1): A5.

  26. Pounder RE, Balley R, Louw JA. GR122311X (ranitidine bismuth citrate) with clarithromycin for the eradication of Helicobacter pylori. Gut 1995; 37 (suppl 1): A42.

  27. Axon ATR, Ireland A, Lancaster-Smith MJ, Roopram PD. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 81-7.

  28. Bardhan KD, Wurzer H, Marcelino M, Jahnsen J, Lotay N. High cure rates with ranitidine bismuth citrate (Pylorid) plus clarithromycin given twice daily. Gut 1996; 39 (suppl 2): A36.

  29. Weeb DD, Ciociola AA, Perschy TB, Goodwin BB. Effect of administration of ranitidine bismuth citrate with food on the suppression and eradication of Helicobacter pylori in infected volunteers. Am J Gastroenterol 1995; 90: 1273-1277.

  30. Graham DY, Hirschowitz B, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus amoxicillin for the treatment of duodenal ulcer disease (abstract). Am J Gastroenterol 1995; 90: 1634: A 638.

  31. Talley NJ. Diagnosis of Helicobacter pylori infection. Inf Med 1994; II (suppl A): 18.

  32. Graham A, Pipkin BS, Jane G, Mills BS, Lata K et al. The safety of ranitidine bismuth citrate in controlled studies. Pharmacoepidemiology and drug safety 1996; 5: 399-407.




2020     |     www.medigraphic.com